Nonalcoholic Fatty Liver Disease Market Growth & Outlook | Major Players 2025 - Pfizer Inc., AstraZeneca, Novartis AG

"The Global Nonalcoholic Fatty Liver Disease (NAFLD) Market is expected to reach at a high CAGR during the forecast period 2023-2030." As per DataM intelligence research report

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/nonalcoholic-fatty-liver-disease-market?sp

United States: Recent Industry Developments

✅ In September 2025, Intercept Pharmaceuticals launched a Phase III trial for its novel FXR agonist targeting NAFLD and NASH patients. The therapy aims to reduce liver fibrosis and improve metabolic outcomes. It leverages advanced biomarkers for patient selection and efficacy monitoring.

✅ In August 2025, Gilead Sciences completed the acquisition of Allurion Therapeutics, expanding its pipeline with innovative therapies for liver disease and metabolic disorders. The move strengthens Gilead's position in hepatology and chronic liver disease management. It integrates complementary drug development and clinical expertise.

✅ In July 2025, Madrigal Pharmaceuticals invested $45 million in its U.S. research facility to accelerate the development of thyroid hormone receptor beta agonists for NAFLD treatment. The funding supports clinical trials and biomarker research. It aims to provide safer and more effective options for patients with fatty liver disease.

✅ In June 2025, Viking Therapeutics launched a novel PPAR-delta agonist candidate for NAFLD, targeting liver inflammation and metabolic dysfunction. The therapy is entering early-phase clinical studies. It is designed to complement lifestyle interventions and existing treatment regimens.

Japan: Recent Industry Developments

✅ In September 2025, Takeda Pharmaceutical initiated a Phase II clinical trial in Japan for a new NAFLD therapeutic combining anti-inflammatory and anti-fibrotic mechanisms. The trial aims to evaluate safety and efficacy in Japanese patients. It supports Takeda's strategy in metabolic liver disease.

✅ In August 2025, Eisai Co., Ltd. invested in expanding its NAFLD-focused R&D division, enhancing capabilities in small-molecule and biologic therapies. The initiative targets development of disease-modifying treatments. It aims to accelerate innovation for patients with liver metabolic disorders.

✅ In July 2025, Otsuka Pharmaceutical completed the acquisition of a Japanese biotech startup developing novel therapeutics for fatty liver disease. The acquisition strengthens its hepatology pipeline. It enables faster clinical development and commercialization of advanced liver therapies.

✅ In June 2025, Sumitomo Dainippon Pharma launched a clinical study for a new NAFLD treatment candidate with dual metabolic and anti-fibrotic activity. The study targets patients with early to moderate liver disease. It supports the company's mission to address unmet needs in hepatology.

Nonalcoholic Fatty Liver Disease Market: Drivers

The nonalcoholic fatty liver disease (NAFLD) therapeutics market is witnessing growth due to the rising prevalence of metabolic disorders, obesity, and diabetes, which are key risk factors for the disease. NAFLD, including its progressive form nonalcoholic steatohepatitis (NASH), is driving demand for effective treatments that can manage liver fat accumulation, inflammation, and fibrosis while improving patient outcomes. Increasing awareness of early diagnosis, preventive care, and lifestyle interventions is encouraging patients and healthcare providers to seek therapeutic solutions. Advances in drug development, including novel small molecules, biologics, and combination therapies, are enhancing treatment efficacy and targeting multiple disease pathways. Additionally, expanding clinical research, government initiatives, and funding for liver disease management are supporting market growth.

Technological innovations in precision medicine, biomarker-driven diagnostics, and non-invasive imaging are improving patient stratification and therapy personalization. Growing emphasis on managing chronic liver conditions and reducing the risk of liver failure or cirrhosis is fueling adoption of emerging therapeutics. Regulatory support for orphan drugs and breakthrough therapies is facilitating faster approval and market entry for promising candidates. Collaborations between pharmaceutical companies, research institutions, and healthcare providers are accelerating clinical development and knowledge dissemination. Collectively, these factors are driving steady growth in the NAFLD therapeutics market as stakeholders focus on effective, personalized, and long-term management of liver health.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/nonalcoholic-fatty-liver-disease-market?sp

Nonalcoholic Fatty Liver Disease Market: Major Players

Pfizer Inc., AstraZeneca, Novartis AG, Takeda Pharmaceutical Company Limited., Intercept Pharmaceuticals, Inc., F. Hoffmann-La Roche Ag, Merck & Co., Inc., Abbvie Inc., And Gilead Sciences, Inc. among others.

Segment Covered in the Nonalcoholic Fatty Liver Disease Market:

➥ By Drug Class: Antioxidants, Lipid-Lowering Drugs, Insulin Sensitizers, Pentoxifylline, Angiotensin Receptor Blockers, Others

➥ By Disease Stage: Non-Alcoholic Steatohepatitis (NASH), Cirrhosis, Fibrosis

➥ By Route of Administration: Injectable, Oral, Others

➥ By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others

Research Process:

Both primary and secondary data sources have been used in the Nonalcoholic Fatty Liver Disease Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Most Frequently Asked Questions in the Nonalcoholic Fatty Liver Disease Market Research Industry:

➠ Who leads the Nonalcoholic Fatty Liver Disease industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do Nonalcoholic Fatty Liver Disease market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting Nonalcoholic Fatty Liver Disease market growth?
➠ What are the dominant sales and distribution strategies in the Nonalcoholic Fatty Liver Disease industry?

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=nonalcoholic-fatty-liver-disease-market

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.